Neuropathic Pain Management — MCQs

10 questions

In a patient with a history of burning pain localized to the plantar aspect of the foot, the differential diagnosis must include -

Which of the following is true about trigeminal neuralgia?

Match the following: A) Glossopharyngeal nerve B) Spinal accessory nerve C) Facial nerve D) Mandibular nerve 1) Shrugging of shoulder 2) Touch sensation from the posterior one-third of the tongue 3) Chewing 4) Taste from the anterior two-thirds of the tongue

A 50-year-old male with diabetes presents with severe burning pain in his feet. Medications have been ineffective. What is the most appropriate next step in management?

Primary afferent fibers secrete which nociceptive substance at the dorsal horn?

Painless burn in hand is seen in:

Which of the following is the most appropriate pharmacological treatment for neuropathic pain in a diabetic patient?

A 35-year-old with migraines needs prophylaxis. Which is suitable?

Sufentanil is classified as a potent:

Q10

Which of the following substances is not classified as an opioid?

Neuropathic Pain Management Indian Medical PG Practice Questions and MCQs

Question 1: In a patient with a history of burning pain localized to the plantar aspect of the foot, the differential diagnosis must include -

A. Peripheral vascular disease
B. Plantar fibromatosis
C. Tarsal tunnel syndrome (Correct Answer)
D. Tarsal coalition

Explanation: ***Tarsal tunnel syndrome*** - This condition involves **compression of the posterior tibial nerve** or its branches as they pass through the tarsal tunnel, leading to **burning pain, numbness, and tingling** on the plantar aspect of the foot [2]. - Symptoms are often exacerbated by activity or prolonged standing and can be reproduced by tapping on the nerve (Tinel's sign). *Peripheral vascular disease* - While it can cause foot pain, it typically presents as **intermittent claudication** (pain with exertion that resolves with rest) or **ischemic rest pain**, often in the toes or forefoot [1]. - The pain is usually described as cramping or aching rather than burning and is associated with signs of **poor circulation** like diminished pulses and cool skin [1]. *Plantar fibromatosis* - This condition, also known as **Ledderhose disease**, involves the formation of benign fibrous nodules within the **plantar fascia**. - It usually presents as **palpable lumps** on the sole of the foot, which may or may not be painful, but burning pain is not a primary or characteristic symptom. *Tarsal coalition* - This is a congenital condition where two or more bones in the midfoot or hindfoot are **abnormally fused**, most commonly the calcaneus and navicular or talus and calcaneus. - It typically causes **pain, stiffness, and flatfoot deformity** that worsens with activity, but burning neuropathic pain is not its primary symptom.

Question 2: Which of the following is true about trigeminal neuralgia?

A. Can be treated with NSAID's
B. Is a hereditary condition
C. Carbamazepine is the drug of choice in trigeminal neuralgia. (Correct Answer)
D. Always bilateral in distribution

Explanation: ***Carbamazepine is the drug of choice in trigeminal neuralgia.*** - **Carbamazepine** is an **anticonvulsant** that is highly effective in reducing the frequency and severity of the paroxysmal pain attacks seen in trigeminal neuralgia. - Its mechanism of action in this condition is thought to involve the **blockade of voltage-gated sodium channels**, reducing neuronal excitability in the trigeminal pathway. *Can be treated with NSAID's* - **Non-steroidal anti-inflammatory drugs (NSAIDs)** are generally **ineffective** in treating the neuropathic, sharp, lancinating pain characteristic of trigeminal neuralgia. - NSAIDs primarily target inflammatory pain, which is not the underlying mechanism of trigeminal neuralgia. *Is a hereditary condition* - Trigeminal neuralgia is typically considered an **acquired condition**, often caused by **vascular compression** of the trigeminal nerve root, rather than a hereditary disorder. - While some rare genetic predispositions to neuropathic pain exist, trigeminal neuralgia itself is not generally inherited. *Always bilateral in distribution* - Trigeminal neuralgia is overwhelmingly **unilateral**, affecting only one side of the face in the distribution of the trigeminal nerve. - **Bilateral involvement** is very rare and, if present, often suggests a **secondary cause** such as multiple sclerosis or a tumor.

Question 3: Match the following: A) Glossopharyngeal nerve B) Spinal accessory nerve C) Facial nerve D) Mandibular nerve 1) Shrugging of shoulder 2) Touch sensation from the posterior one-third of the tongue 3) Chewing 4) Taste from the anterior two-thirds of the tongue

A. A-3 , B-1 , C-4 , D-2
B. A-2 , B-3 , C-4 , D-1
C. A-4 , B-1 , C-2 , D-3
D. A-2 , B-1 , C-4 , D-3 (Correct Answer)

Explanation: ***A-2 , B-1 , C-4 , D-3*** - **A) Glossopharyngeal nerve (CN IX)** is responsible for **general sensation and taste from the posterior one-third of the tongue** [1]. (2). - **B) Spinal Accessory nerve (CN XI)** innervates the **sternocleidomastoid** and **trapezius muscles**, which are involved in shrugging the shoulders (1). - **C) Facial nerve (CN VII)** carries **taste sensation from the anterior two-thirds of the tongue** [1] (4) via the chorda tympani. - **D) Mandibular nerve (V3)**, a branch of the trigeminal nerve, innervates the muscles of mastication, enabling **chewing** (3). *A-3 , B-1 , C-4 , D-2* - This option incorrectly associates the **glossopharyngeal nerve** with chewing, which is a function of the mandibular nerve (V3). - It also incorrectly associates the **mandibular nerve** with touch sensation from the posterior one-third of the tongue, which is a function of the glossopharyngeal nerve [1]. *A-2 , B-3 , C-4 , D-1* - This option incorrectly links the **spinal accessory nerve** with chewing; this nerve primarily controls shoulder and neck movements. - It also incorrectly assigns shrugging of the shoulder to the **mandibular nerve** instead of the spinal accessory nerve. *A-4 , B-1 , C-2 , D-3* - This choice incorrectly attributes **taste from the anterior two-thirds of the tongue** to the glossopharyngeal nerve, which supplies the posterior one-third [1]. - It also incorrectly links **touch sensation from the posterior one-third of the tongue** to the facial nerve, which is involved in taste from the anterior two-thirds [1].

Question 4: A 50-year-old male with diabetes presents with severe burning pain in his feet. Medications have been ineffective. What is the most appropriate next step in management?

A. Prescribe opioid analgesics
B. Prescribe corticosteroids
C. Trial of pregabalin (Correct Answer)
D. Refer for physical therapy

Explanation: ***Trial of pregabalin*** - **Pregabalin**, a gamma-aminobutyric acid (GABA) analog, is a first-line treatment for **diabetic neuropathic pain** due to its efficacy in modulating neurotransmitter release [2]. - Given that previous medications have been ineffective for **severe burning pain** [1] in diabetic neuropathy, exploring other pharmacological options like pregabalin is the most appropriate next step [2]. *Prescribe opioid analgesics* - **Opioid analgesics** are generally reserved for neuropathic pain that is refractory to other treatments due to concerns about tolerance, dependence, and significant side effects [1]. - They are not considered a first-line or early second-line treatment for **diabetic neuropathy**, especially when other agents like pregabalin have not yet been trialed [2]. *Prescribe corticosteroids* - **Corticosteroids** are potent anti-inflammatory agents but are not indicated for the chronic management of **diabetic neuropathic pain**, which is primarily a nerve damage issue rather than an inflammatory one. - Long-term steroid use carries significant risks and would likely worsen diabetes control, making it an inappropriate choice. *Refer for physical therapy* - **Physical therapy** can be beneficial for managing some aspects of diabetic neuropathy, such as improving balance or muscle strength, but it is unlikely to directly alleviate severe burning neuropathic pain as a primary monotherapy. - While a valuable adjunctive treatment, it is not the most appropriate initial next step for directly addressing severe pain symptoms when pharmacological options are still available [2].

Question 5: Primary afferent fibers secrete which nociceptive substance at the dorsal horn?

A. Substance P (Correct Answer)
B. Acetylcholine
C. Norepinephrine
D. Epinephrine

Explanation: ***Substance P*** - **Substance P** is a neuropeptide released by **C fibers** and **A-delta fibers** (primary afferent nociceptors) in the dorsal horn of the spinal cord. - It acts as a **neurotransmitter** and **neuromodulator**, contributing to the transmission and amplification of pain signals. *Acetylcholine* - **Acetylcholine** is a primary neurotransmitter in the **neuromuscular junction** and the autonomic nervous system. - While it has some roles in the CNS, it is not the primary nociceptive substance secreted by afferent fibers in the dorsal horn. *Norepinephrine* - **Norepinephrine** (noradrenaline) is a neurotransmitter involved in the **fight-or-flight response** and mood regulation. - It can modulate pain, but it is not directly released by primary afferent fibers as a nociceptive substance in the dorsal horn. *Epinephrine* - **Epinephrine** (adrenaline) is a hormone and neurotransmitter primarily associated with the **sympathetic nervous system** and stress response. - It does not serve as a direct nociceptive transmitter released by primary afferent fibers in the spinal cord.

Question 6: Painless burn in hand is seen in:

A. SLE
B. Mononeuritis multiplex
C. Diabetes mellitus
D. Syringomyelia (Correct Answer)

Explanation: ***Syringomyelia*** - Syringomyelia is characterized by a fluid-filled cavity (syrinx) within the **spinal cord**, which can damage nerve fibers responsible for pain and temperature sensation. - This damage leads to a **dissociated sensory loss**, where patients lose the ability to feel pain and temperature but retain touch and vibration, making them susceptible to **painless burns** or injuries. *SLE* - **Systemic lupus erythematosus (SLE)** is an autoimmune disease that can affect various organs, but it does not typically cause a dissociated sensory loss leading to painless burns. - Neurological manifestations in SLE are diverse, ranging from headaches to seizures, but they rarely involve selective loss of pain and temperature sensation in a way that causes painless burns. *Mononeuritis multiplex* - **Mononeuritis multiplex** involves damage to at least two distinct nerve areas, often causing pain, weakness, and sensory loss in a patchy distribution, but usually includes pain. - This condition is not typically characterized by a complete and selective loss of **pain and temperature sensation** in a way that would lead to painless burns without other significant sensory deficits. *Diabetes mellitus* - **Diabetic neuropathy** commonly causes sensory loss, often a "stocking-glove" distribution, which can lead to painless injuries due to reduced pain sensation. - However, diabetic neuropathy primarily affects **small fiber nerves** and is more generalized, unlike the more selective **dissociated sensory loss** seen in syringomyelia that specifically explains painless burns.

Question 7: Which of the following is the most appropriate pharmacological treatment for neuropathic pain in a diabetic patient?

A. Acetaminophen
B. Tramadol
C. Aspirin
D. Gabapentin (Correct Answer)

Explanation: ***Gabapentin*** - **Gabapentin** is a widely recommended first-line treatment for diabetic neuropathic pain due to its efficacy in modulating neuronal excitability. - It works by binding to the **α2δ subunit of voltage-gated calcium channels**, reducing calcium influx and thereby decreasing the release of excitatory neurotransmitters involved in pain signaling. *Acetaminophen* - **Acetaminophen** is primarily an analgesic and antipyretic, effective for mild to moderate non-neuropathic pain. - It has no significant efficacy against **neuropathic pain**, which involves distinct neurobiological mechanisms. *Tramadol* - **Tramadol** is an opioid analgesic with some serotonin and norepinephrine reuptake inhibition, offering moderate pain relief. - While it can be used for moderate to severe pain, it is generally considered a **second-line agent** for neuropathic pain due to its opioid nature and potential side effects. *Aspirin* - **Aspirin** is a nonsteroidal anti-inflammatory drug (NSAID) primarily used for its anti-inflammatory, analgesic, and antiplatelet effects. - It is **ineffective for neuropathic pain**, which does not typically involve peripheral inflammation as its primary mechanism.

Question 8: A 35-year-old with migraines needs prophylaxis. Which is suitable?

A. Acetaminophen
B. Sumatriptan
C. Verapamil (Correct Answer)
D. Tramadol

Explanation: ***Verapamil*** - **Verapamil**, a calcium channel blocker, is often used off-label for **migraine prophylaxis**, particularly in cases where other first-line agents are contraindicated or ineffective. - While not a first-line treatment, it can reduce the frequency and severity of migraine attacks by modulating **vasoconstriction** and **vasodilation**. *Acetaminophen* - **Acetaminophen** is an analgesic used for **acute pain relief**, but it does not have properties that prevent migraine attacks from occurring. - It is unsuitable for long-term **prophylactic management** of migraines. *Sumatriptan* - **Sumatriptan** is a **triptan** medication used for **acute migraine treatment**, meaning it is taken to stop a migraine attack once it has started. - It is not indicated for **migraine prophylaxis** and should not be used regularly to prevent migraines. *Tramadol* - **Tramadol** is an **opioid analgesic** used for moderate to severe pain, and it carries risks of dependence and side effects. - It is not recommended for **migraine prophylaxis** due to its addictive potential and lack of evidence for preventing migraine attacks.

Question 9: Sufentanil is classified as a potent:

A. Myocardial depressant
B. Analgesic (Correct Answer)
C. Hepatotoxin
D. Anticonvulsant

Explanation: ***Analgesic*** - **Sufentanil** is a synthetic **opioid analgesic** primarily used for its potent pain-relieving effects, especially in surgical and intensive care settings - It acts by binding to and activating **μ-opioid receptors** in the central nervous system, reducing the perception of pain - Approximately **5-10 times more potent than fentanyl**, making it one of the most potent opioid analgesics available - Commonly used in **anesthesia** for its rapid onset and short duration of action *Myocardial depressant* - While high doses of some anesthetic agents can cause myocardial depression, sufentanil has **minimal direct myocardial depressant effects** in clinically relevant doses - Its primary classification is not as a direct cardiac depressant, although it can cause **bradycardia** and hypotension through **vagal stimulation** and decreased sympathetic tone *Hepatotoxin* - There is **no significant evidence** classifying sufentanil as a hepatotoxin that causes liver damage - Liver toxicity is more commonly associated with drugs like **acetaminophen in overdose** or certain anesthetics like **halothane** - Sufentanil is extensively metabolized by the liver but does not cause hepatotoxicity *Anticonvulsant* - **Sufentanil** does not possess anticonvulsant properties - Opioids generally do not have seizure prevention effects and may occasionally lower the seizure threshold, though this is rare with sufentanil at therapeutic doses - Anticonvulsants are a separate class of drugs (e.g., phenytoin, valproate, levetiracetam) used to prevent or reduce seizures

Question 10: Which of the following substances is not classified as an opioid?

A. Heroin
B. Ketamine (Correct Answer)
C. Methadone
D. Fentanyl

Explanation: ***Ketamine*** - **Ketamine** is classified as a **dissociative anesthetic** and does not act on opioid receptors. - Its primary mechanism of action involves **N-methyl-D-aspartate (NMDA) receptor antagonism**. *Heroin* - **Heroin** (diacetylmorphine) is a **semisynthetic opioid** derived from morphine [1, 3]. - It rapidly crosses the **blood-brain barrier** and is metabolized to morphine, where it acts as a potent **mu-opioid receptor agonist** [3]. *Methadone* - **Methadone** is a **synthetic opioid** used in the treatment of opioid dependence and chronic pain [1, 2]. - It acts primarily as a **mu-opioid receptor agonist** with a long duration of action [1, 2]. *Fentanyl* - **Fentanyl** is a powerful **synthetic opioid** analgesic, much more potent than morphine [2]. - It selectively binds to and activates **mu-opioid receptors**, producing strong analgesic and sedative effects [2].

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free